Back to search results

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

Israel
RecruitingPHASE3

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Conditions

Primary IgA Nephropathy

Locations
  • AZ Kidney Dise and Hypertension Ctr, Glendale, Arizona, United States
  • Kaiser Permanente, San Diego, California, United States
  • North America Research Institute, San Dimas, California, United States
  • University of Colorado Anschutz, Aurora, Colorado, United States
  • Nephrology Associates PA, Newark, Delaware, United States
  • CaRe Research, Chubbuck, Idaho, United States
  • Nep Assoc of Northern Illinois, Hinsdale, Illinois, United States
  • Johns Hopkins Hospital, Baltimore, Maryland, United States
  • Brigham and Womens Hosp Harvard Med School, Boston, Massachusetts, United States
  • Mayo Clinic Rochester, Rochester, Minnesota, United States
  • Clin Rsrch Consult a JCCT Company, Kansas City, Missouri, United States
  • DaVita Clinical Research, Las Vegas, Nevada, United States
  • New Jersey Kidney Care, Jersey City, New Jersey, United States
  • Col Uni Med Center New York Presby, New York, New York, United States
  • Dallas Renal Group, Dallas, Texas, United States
  • Prolato Clinical Research Center, Houston, Texas, United States
  • Novartis Investigative Site, Córdoba, Córdoba Province, Argentina
  • Novartis Investigative Site, Córdoba, Córdoba Province, Argentina
  • Novartis Investigative Site, CABA, Argentina
  • Novartis Investigative Site, CABA, Argentina
  • Novartis Investigative Site, Santa Fe, Argentina
  • Novartis Investigative Site, Woolloongabba, Queensland, Australia
  • Novartis Investigative Site, Adelaide, South Australia, Australia
  • Novartis Investigative Site, Parkville, Victoria, Australia
  • Novartis Investigative Site, Roeselare, West-Vlaanderen, Belgium
  • Novartis Investigative Site, Edegem, Belgium
  • Novartis Investigative Site, Leuven, Belgium
  • Novartis Investigative Site, Belo Horizonte, Minas Gerais, Brazil
  • Novartis Investigative Site, Curitiba, Paraná, Brazil
  • Novartis Investigative Site, Porto Alegre, Rio Grande do Sul, Brazil
  • Novartis Investigative Site, São Paulo, São Paulo, Brazil
  • Novartis Investigative Site, São Paulo, São Paulo, Brazil
  • Novartis Investigative Site, Sao Jose Rio Preto, Brazil
  • Novartis Investigative Site, Oshawa, Ontario, Canada
  • Novartis Investigative Site, Temuco, Chile
  • Novartis Investigative Site, Beijing, Beijing Municipality, China
  • Novartis Investigative Site, Beijing, Beijing Municipality, China
  • Novartis Investigative Site, Guangzhou, Guangdong, China
  • Novartis Investigative Site, Luoyang, Henan, China
  • Novartis Investigative Site, Zhengzhou, Henan, China
  • Novartis Investigative Site, Changsha, Hunan, China
  • Novartis Investigative Site, Changchun, Jilin, China
  • Novartis Investigative Site, Yinchuan, Ningxia, China
  • Novartis Investigative Site, Taiyuan, Shanxi, China
  • Novartis Investigative Site, Xian, Shanxi, China
  • Novartis Investigative Site, Ürümqi, Xinjiang, China
  • Novartis Investigative Site, Ningbo, Zhejiang, China
  • Novartis Investigative Site, Wenzhou, Zhejiang, China
  • Novartis Investigative Site, Beijing, China
  • Novartis Investigative Site, Guangzhou, China
  • Novartis Investigative Site, Ningbo, China
  • Novartis Investigative Site, Qingdao, China
  • Novartis Investigative Site, Shanghai, China
  • Novartis Investigative Site, Shanghai, China
  • Novartis Investigative Site, Shenzhen, China
  • Novartis Investigative Site, Medellín, Antioquia, Colombia
  • Novartis Investigative Site, Barranquilla, Atlántico, Colombia
  • Novartis Investigative Site, Prague, Czechia
  • Novartis Investigative Site, Aalborg, Denmark
  • Novartis Investigative Site, Aarhus N, Denmark
  • Novartis Investigative Site, Copenhagen, Denmark
  • Novartis Investigative Site, Odense C, Denmark
  • Novartis Investigative Site, Marseille, France
  • Novartis Investigative Site, Montpellier, France
  • Novartis Investigative Site, Paris, France
  • Novartis Investigative Site, Freiburg im Breisgau, Baden-Wurttemberg, Germany
  • Novartis Investigative Site, Stuttgart, Baden-Wurttemberg, Germany
  • Novartis Investigative Site, Aachen, Germany
  • Novartis Investigative Site, Berlin, Germany
  • Novartis Investigative Site, Essen, Germany
  • Novartis Investigative Site, Hanover, Germany
  • Novartis Investigative Site, Heidelberg, Germany
  • Novartis Investigative Site, Kiel, Germany
  • Novartis Investigative Site, Magdeburg, Germany
  • Novartis Investigative Site, Mainz, Germany
  • Novartis Investigative Site, Tübingen, Germany
  • Novartis Investigative Site, Ulm, Germany
  • Novartis Investigative Site, Hong Kong, Hong Kong, Hong Kong
  • Novartis Investigative Site, Pécs, Baranya, Hungary
  • Novartis Investigative Site, Debrecen, Hajdu Bihar Megye, Hungary
  • Novartis Investigative Site, Bangalore, Karnataka, India
  • Novartis Investigative Site, New Delhi, National Capital Territory of Delhi, India
  • Novartis Investigative Site, New Delhi, National Capital Territory of Delhi, India
  • Novartis Investigative Site, Hyderabad, Telangana, India
  • Novartis Investigative Site, Ashkelon, Israel
  • Novartis Investigative Site, Jerusalem, Israel
  • Novartis Investigative Site, Petah Tikva, Israel
  • Novartis Investigative Site, Bologna, BO, Italy
  • Novartis Investigative Site, Naples, Italy
  • Novartis Investigative Site, Kasugai, Aichi-ken, Japan
  • Novartis Investigative Site, Toyoake, Aichi-ken, Japan
  • Novartis Investigative Site, Toyota, Aichi-ken, Japan
  • Novartis Investigative Site, Sapporo, Hokkaido, Japan
  • Novartis Investigative Site, Sapporo, Hokkaido, Japan
  • Novartis Investigative Site, Kawasaki, Kanagawa, Japan
  • Novartis Investigative Site, Yokohama, Kanagawa, Japan
  • Novartis Investigative Site, Yokohama, Kanagawa-ku, Japan
  • Novartis Investigative Site, Kyoto, Kyoto, Japan
  • Novartis Investigative Site, Sendai, Miyagi, Japan
  • Novartis Investigative Site, Matsumoto, Nagano, Japan
  • Novartis Investigative Site, Osaka, Osaka, Japan
  • Novartis Investigative Site, Ōmihachiman, Shiga, Japan
  • Novartis Investigative Site, Chiba, Japan
  • Novartis Investigative Site, Niigata, Japan
  • Novartis Investigative Site, Okayama, Japan
  • Novartis Investigative Site, Osaka, Japan
  • Novartis Investigative Site, Osaka, Japan
  • Novartis Investigative Site, Kuala Lumpur, Kuala Lumpur, Malaysia
  • Novartis Investigative Site, Kuala Lumpur, Malaysia
  • Novartis Investigative Site, Mexico City, Mexico
  • Novartis Investigative Site, Querétaro, Mexico
  • Novartis Investigative Site, Groningen, Provincie Groningen, Netherlands
  • Novartis Investigative Site, Nordbyhagen, Oslo, Norway
  • Novartis Investigative Site, Bergen, Norway
  • Novartis Investigative Site, Rostov-on-Don, Russia
  • Novartis Investigative Site, Saint Petersburg, Russia
  • Novartis Investigative Site, Singapore, Singapore
  • Novartis Investigative Site, Singapore, Singapore
  • Novartis Investigative Site, Košice, Slovakia
  • Novartis Investigative Site, Maribor, Slovenia, Slovenia
  • Novartis Investigative Site, Ljubljana, Slovenia
  • Novartis Investigative Site, Bloemfontein, Free State, South Africa
  • Novartis Investigative Site, Bundang Gu, Gyeonggi-do, South Korea
  • Novartis Investigative Site, Seoul, Korea, South Korea
  • Novartis Investigative Site, Seoul, Korea, South Korea
  • Novartis Investigative Site, Seoul, Korea, South Korea
  • Novartis Investigative Site, Cheongju-si, North Chungcheong, South Korea
  • Novartis Investigative Site, Busan, South Korea
  • Novartis Investigative Site, Seoul, South Korea
  • Novartis Investigative Site, Seoul, South Korea
  • Novartis Investigative Site, Seoul, South Korea
  • Novartis Investigative Site, Seoul, South Korea
  • Novartis Investigative Site, Taegu, South Korea
  • Novartis Investigative Site, Pamplona, Navarre, Spain
  • Novartis Investigative Site, Barcelona, Spain
  • Novartis Investigative Site, Salamanca, Spain
  • Novartis Investigative Site, Stockholm, Sweden
  • Novartis Investigative Site, Kaohsiung City, Taiwan
  • Novartis Investigative Site, New Taipei City, Taiwan
  • Novartis Investigative Site, New Taipei City, Taiwan
  • Novartis Investigative Site, Taichung, Taiwan
  • Novartis Investigative Site, Taichung, Taiwan
  • Novartis Investigative Site, Taipei, Taiwan
  • Novartis Investigative Site, Taoyuan District, Taiwan
  • Novartis Investigative Site, Bangkok, Thailand
  • Novartis Investigative Site, Bangkok, Thailand
  • Novartis Investigative Site, Bangkok, Thailand
  • Novartis Investigative Site, Istanbul, Fatih, Turkey (Türkiye)
  • Novartis Investigative Site, Köseköy, Kocaeli, Turkey (Türkiye)
  • Novartis Investigative Site, Antalya, Konyaalti, Turkey (Türkiye)
  • Novartis Investigative Site, Kayseri, Melikgazi, Turkey (Türkiye)
  • Novartis Investigative Site, Istanbul, Sariyer, Turkey (Türkiye)
  • Novartis Investigative Site, Ankara, Yenimahalle, Turkey (Türkiye)
  • Novartis Investigative Site, Mersin, Yenisehir, Turkey (Türkiye)
  • Novartis Investigative Site, Newcastle upon Tyne, Tyne and Wear, United Kingdom
  • Novartis Investigative Site, Cambridge, United Kingdom
  • Novartis Investigative Site, Leicester, United Kingdom
  • Novartis Investigative Site, London, United Kingdom
  • Novartis Investigative Site, Salford, United Kingdom
  • Novartis Investigative Site, Ho Chi Minh City, VNM, Vietnam
  • Novartis Investigative Site, Ho Chi Minh City, Vietnam
View source on ClinicalTrials.gov(opens in a new tab)Contact study team (email)